Company profile
CORCEPT THERAPEUTICS INC
NASDAQ:CORTBiotechnology: Pharmaceutical Preparations
Drug pipeline (4)
| Asset | Stage | Revenue | Trials | Status |
|---|---|---|---|---|
| MIFEPRISTONE | approved | — | 19 | approved |
| RELACORILANT | approved | — | 19 | approved |
| Dazucorilant | phase1 | — | 1 | no active trials |
| MIRICORILANT | phase1 | — | 3 | no active trials |
Revenue is the latest reported period from SEC filings. A combination product's amount appears on each of its constituent assets, so those rows are not additive.
Clinical trials (67)
| NCT ID | Phase | Status | Start | Completion | Sponsor name | Title |
|---|---|---|---|---|---|---|
| NCT00698022 | phase1 | completed | 2008-11-01 | 2009-02-01 | Corcept Therapeutics | A 4-week Study of Mifepristone in the Prevention of Risperidone-induced Weight Gain in Healthy Male Volunteers |
| NCT06108219 | phase2 | active_not_recruiting | 2023-10-25 | 2026-09-01 | Corcept Therapeutics | A Phase 2b, Study Evaluating Miricorilant in Adult Patients With Nonalcoholic Steatohepatitis/Metabolic Dysfunction-Associated Steatohepatitis (MONARCH) |
| NCT00752843 | phase1 | completed | 2008-09-01 | 2008-11-01 | Corcept Therapeutics | A Phase I Study to Determine the Effect of Mifepristone on the Pharmacokinetics of Fluvastatin in Healthy Volunteers |
| NCT03067376 | phase1 | completed | 2016-08-01 | 2016-09-01 | Corcept Therapeutics | A Study Designed to See How [14C]-CORT125134 is Taken up, Broken Down and Removed From the Body |
| NCT04524403 | phase2 | completed | 2020-09-09 | 2022-07-29 | Corcept Therapeutics | A Study Evaluating the Safety, Efficacy, and Pharmacokinetics of Miricorilant in Obese Adult Patients With Schizophrenia While Taking Antipsychotic Medications (GRATITUDE II) |
FDA applications (2)
| Application | Type | Applicant | Products | |||
|---|---|---|---|---|---|---|
| NDA 202107 | NDA | CORCEPT THERAPEUTICS INC | ||||
Loading… | ||||||
| NDA 220641 | NDA | CORCEPT THERAPEUTICS INC | ||||
Loading… | ||||||